Metformin, a commonly prescribed ﬁrst-line antidiabetic drug, has proven tobe safe and efﬁcacious when used asmonotherapy or in combination withother oral antidiabetic agents or insulin inpatients with type 2 diabetes (7–10).However, for patients failing to achieveoptimal glycemic control with met-formin, many of the currently availabletreatment choices come with the above- mentioned undesirable side effects andthe likelihood of eventual loss of glycemiccontrol (2,3,7–10). Exenatide (exendin-4) is a 39–amino